KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Finished Goods (2016)

Historic Finished Goods for AbbVie (ABBV) over the last 5 years, with Q2 2016 value amounting to $556.0 million.

  • AbbVie's Finished Goods rose 1631.8% to $556.0 million in Q2 2016 from the same period last year, while for Jun 2016 it was $556.0 million, marking a year-over-year increase of 1631.8%. This contributed to the annual value of $469.0 million for FY2015, which is 3753.67% up from last year.
  • According to the latest figures from Q2 2016, AbbVie's Finished Goods is $556.0 million, which was up 1631.8% from $552.0 million recorded in Q1 2016.
  • In the past 5 years, AbbVie's Finished Goods ranged from a high of $640.0 million in Q3 2015 and a low of $280.0 million during Q3 2014
  • Over the past 5 years, AbbVie's median Finished Goods value was $485.0 million (recorded in 2013), while the average stood at $479.5 million.
  • Its Finished Goods has fluctuated over the past 5 years, first crashed by 4142.26% in 2014, then soared by 12857.14% in 2015.
  • AbbVie's Finished Goods (Quarter) stood at $547.0 million in 2012, then dropped by 11.33% to $485.0 million in 2013, then decreased by 29.69% to $341.0 million in 2014, then soared by 37.54% to $469.0 million in 2015, then grew by 18.55% to $556.0 million in 2016.
  • Its Finished Goods was $556.0 million in Q2 2016, compared to $552.0 million in Q1 2016 and $469.0 million in Q4 2015.